Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
01 avr. 2024 18h08 HE
|
Ocugen
Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical TrialDSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) --...
Global Ophthalmology EMR Software Market to Reach USD 504.92 Million by 2028 – Extensive Report Analyzes Impact of COVID-19, Market Dynamics, and Competitive Landscape
27 mars 2024 13h06 HE
|
Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Global Ophthalmology EMR Software Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ...
Global Intraocular Lens Market Expected to Reach USD 9.82 Billion by 2034
27 mars 2024 08h40 HE
|
Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Global Intraocular Lens Market Analysis & Forecast 2024-2034: Market By Product; By Material; By End-user; and By Region" report has been added to...
Global Diabetic Macular Edema Treatment Market by Treatment (Corticosteroid Injections, Drugs, Laser Treatment), End-User (Hospitals, Ophthalmology Clinics) - Forecast 2024-2030
19 mars 2024 17h52 HE
|
Research and Markets
Dublin, March 19, 2024 (GLOBE NEWSWIRE) -- The "Global Diabetic Macular Edema Treatment Market by Treatment (Corticosteroid Injections, Drugs, Laser Treatment), End-User (Hospitals, Ophthalmology...
Global Anterior Uveitis Treatment Market by Treatment Type (Anti-Tumor Necrosis Factor Agents, Corticosteroids, Cycloplegic Agents), Distribution Channel - Forecast 2024-2030
19 mars 2024 17h49 HE
|
Research and Markets
Dublin, March 19, 2024 (GLOBE NEWSWIRE) -- The "Global Anterior Uveitis Treatment Market by Treatment Type (Anti-Tumor Necrosis Factor Agents, Corticosteroids, Cycloplegic Agents), Distribution...
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
19 mars 2024 14h20 HE
|
Spherix Global Insights
EXTON, PA, March 19, 2024 (GLOBE NEWSWIRE) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising...
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
18 mars 2024 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
18 mars 2024 06h30 HE
|
Ocugen
MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Medical Biomimetics Market Size is projected to reach USD 54.25 billion by 2031, growing at a CAGR of 6.5%: Straits Research
14 mars 2024 09h20 HE
|
Straits Research Private Limited
New York, United States, March 14, 2024 (GLOBE NEWSWIRE) -- Medical biomimetics, also known as biomimicry or bioinspired technology, is a field that creates and develops novel medical treatments,...
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
13 mars 2024 08h00 HE
|
Ocugen
MALVERN, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...